Eli Lilly and Company, Chimerix, and Johnson & Johnson are the three Pharmaceutical stocks to watch today, according to MarketBeat’s stock screener tool. Pharmaceutical stocks are shares of companies ...

Experiments in rats suggest that reduced dopamine receptor availability in the ... Rats selected in this way also had reduced levels of available DRD2 in ventral striata, as detected by ...

Dordaviprone is designed to activate stress responses in cancer cells, pushing them into apoptosis by acting on the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). According to ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

Dopamine receptors are a primary target of the SGAs, and many studies have tested whether variation in the dopamine receptor genes correlate with treatment response and/or side effect profiles.